NASDAQ:CRDL Cardiol Therapeutics Q2 2026 Earnings Results & Report $1.23 -0.07 (-5.38%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$1.26 +0.03 (+2.20%) As of 10/9/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Cardiol Therapeutics beat analyst earnings expectations in its Q2 2026 results, released August 13, 2026. The company reported EPS of -$0.04 versus the -$0.09 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 13, 2026TimeBefore Market OpensConference Call DateAugust 12, 2026Conference Call4:00 PM ET Cardiol Therapeutics EPS ResultsActual EPS-$0.04Consensus EPS -$0.09Beat/MissBeat by +$0.05One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersCardiol Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsCardiol Therapeutics' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile Cardiol Therapeutics Q2 2026 Earnings FAQ Did Cardiol Therapeutics beat earnings estimates for Q2 2026? Cardiol Therapeutics (NASDAQ:CRDL) reported earnings of -$0.04 per share for Q2 2026, beating the consensus estimate of -$0.09. The report was announced on Thursday, August 13, 2026. When is Cardiol Therapeutics' next earnings date? Cardiol Therapeutics' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Cardiol Therapeutics on the company's earnings history page. Cardiol Therapeutics Earnings HeadlinesAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Cardiol Therapeutics (CRDL), Tyra Bioscience (TYRA) and Alibaba Health Information Technology (OtherALBHF)September 24, 2026 | theglobeandmail.comCardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s EfficacySeptember 23, 2026 | prnewswire.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.October 10 at 1:00 AM | Banyan Hill Publishing (Ad)Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in ProceedsSeptember 16, 2026 | prnewswire.comCardiol Therapeutics Details Long-Term Manufacturing and Development Agreements in September SEC FilingSeptember 11, 2026 | tipranks.comCardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities CommissionSeptember 10, 2026 | prnewswire.comSee More Cardiol Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cardiol Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiol Therapeutics and other key companies, straight to your email. Email Address About Cardiol TherapeuticsCardiol Therapeutics (NASDAQ:CRDL) is a Canadian clinical-stage biotechnology company focused on developing therapies for inflammatory diseases of the heart and other cardiovascular conditions. The company is headquartered in Burlington, Ontario, and its shares trade on the Nasdaq Capital Market under the symbol CRDL. Cardiol’s lead product candidate, CardiolRx, is a pharmaceutical formulation of cannabidiol being investigated for its potential anti-inflammatory and cardioprotective properties. The company’s research has focused on conditions including acute myocarditis, an inflammation of the heart muscle, and recurrent pericarditis, an inflammatory disorder affecting the sac surrounding the heart. Cardiol conducts clinical development activities through research and trial programs in North America and other regions. The company is led by David Elsley, who serves as president and chief executive officer, with scientific and medical programs supported by researchers and clinicians specializing in cardiovascular disease and inflammation.View Cardiol Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
